<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics? · Newsletter</title>
<style>
:root{--bg:#0f1221;--fg:#e8ecf3;--muted:#98a2b3;--link:#74b7ff;--card:#171b2f;--btn:#2563eb;--btnText:#fff;}
*{box-sizing:border-box} body{margin:0;font-family:ui-sans-serif,system-ui,-apple-system,Segoe UI,Roboto,Inter,Arial;background:var(--bg);color:var(--fg)}
.container{max-width:920px;margin:40px auto;padding:0 16px}
.header{display:flex;justify-content:space-between;align-items:center;gap:16px}
.brand{font-size:.95rem;font-weight:700;color:#8fb5ff}
.kicker{font-size:.85rem;color:var(--muted)}
.card{background:var(--card);border-radius:14px;padding:26px;margin-top:18px;box-shadow:0 6px 24px rgba(0,0,0,.35)}
h1{font-size:2rem;margin:.2rem 0 0}
.meta{font-size:.9rem;color:var(--muted);margin:.6rem 0 1rem}
ul{margin:12px 0 18px 22px;padding:0}
li{margin:.35rem 0;line-height:1.5}
a{color:var(--link);text-decoration:none}
a:hover{text-decoration:underline}
.btns{display:flex;gap:10px;margin-top:10px}
.btn{display:inline-block;background:transparent;border:1px solid #6b7280;color:#e5e7eb;padding:8px 12px;border-radius:8px;font-size:.9rem}
.btn.primary{background:var(--btn);border-color:var(--btn);color:var(--btnText)}
.footer{margin-top:26px;font-size:.8rem;color:var(--muted);text-align:center}
hr{border:0;border-top:1px solid #2a2f48;margin:18px 0}
</style>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">Daily Finance Newsletter</div>
      <div class="kicker">5–7 key bullets per story</div>
    </div>

    <div class="card">
      <h1>Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?</h1>
      <div class="meta">2025-09-15 08:00:00+00:00 UTC</div>
      <ul>
        <li>Moderna, which continues its work on vaccines, recently announced plans to lay off 10% of its workforce following the dip in COVID-relarted demand and lackluster sales of its RSV vaccine.</li>
        <li>The FDA granted the phase 2 candidate fast track status.</li>
        <li>HHS also recently deprioritized mRNA vaccine development, pulling $500 million in funding from projects, and voicing support for a shift to other vaccine platforms.</li>
        <li>The company recently secured $153 million in series B funding, even amid a significant contraction in biotech investment, showing enthusiasm for the platform, Becraft said.</li>
        <li>Over the next 10 to 15 years, this could lead to expanded opportunities with other companies.</li>
        <li>It’s also testing the drug in phase 2 kidney cancer and bladder cancer, among others, according to a second-quarter update.</li>
        <li>In May, Strand released promising interim phase 1 results for its lead candidate STX-001 in melanoma and other solid tumors.</li>
      </ul>
      <div class="btns">
        <a class="btn" href="https://finance.yahoo.com/m/8ed7d118-5f72-3e00-b57e-fdc4bb36dfca/moderna-and-biontech.html" target="_blank" rel="noopener nofollow">Original</a>
        <a class="btn primary" href="https://twitter.com/intent/tweet?text=Moderna+and+BioNTech+pioneered+mRNA+vaccines.+But+who+will+make+a+mark+in+therapeutics%3F%0A%E2%80%A2+Moderna%2C+which+continues+its+work+on+vaccines%2C+recently+announced+plans+to+lay+off+10%25+of+its+workforce+following+the+dip+in+COVID-relarted+demand+and+lackluster+sa%E2%80%A6%0Ahttps%3A%2F%2Ffinance.yahoo.com%2Fm%2F8ed7d118-5f72-3e00-b57e-fdc4bb36dfca%2Fmoderna-and-biontech.html" target="_blank" rel="noopener">Share on X</a>
      </div>
      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </div>
</body>
</html>
